NSCLC, metastatic 1

LBA49 - Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study

Edward B. Garon, et al. 

Conclusions

Antitumor activity and safety in adv/met NSCLC pts with AGAs are encouraging. The ongoing phase 2 TROPION-Lung05 trial (NCT04484142) is assessing Dato-DXd at 6 mg/kg in adv/met NSCLC with AGAs after targeted therapies and platinum chemotherapy.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/LBA49.html.pdf

  

1192MO - Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study

Natasha B. Leighl, et al. 

Conclusions

Antitumor activity of ami + laz in the post-osi setting appears favorable even without molecular selection post osimertinib failure, supporting that simultaneous targeting of the extracellular and catalytic domains of EGFR provides additive benefits.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/1192MO.html.pdf

  

1193MO - Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2

Catherine A. Shu, et al. 

Conclusions

Ami + laz is showing encouraging early activity in a population that progressed on both standard of care osi and platinum chemotherapy. Activity is consistent with the post-osi population, suggesting intervening chemotherapy does not impact ami + laz activity.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/1193MO.html.pdf

  

LBA50 - A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naïve patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22

Anne-Marie C. Dingemans, et al. 

Conclusions

CPB did not improve PFS compared to cis-pem in pts with advanced KRAS mutated NSCLC.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/LBA50.html.pdf

  

LBA51 - EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)

Miranda Gogishvili, et al. 

Conclusions

In pts with advanced NSCLC, 1L cemiplimab+chemo demonstrated clinically meaningful and statistically significant improvement in OS, PFS, ORR and DOR vs chemo alone, with a safety profile consistent with cemiplimab monotherapy and platinum-based chemo.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/LBA51.html.pdf

 

1194MO - Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results

Luis Paz-Ares, et al.

Conclusions

Addition of CAN to DTX in the 2/3L setting did not improve OS or PFS in pts with advanced NSCLC. Safety profiles were comparable between the 2 arms, but a numerically higher incidence of infections (including fatal infections) occurred with CAN. Biomarker analysis is ongoing.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/1194MO.html.pdf